<p>Shaorong Chong of New England Biolabs in the U.S. will synthetically reconstruct essential biological processes of Mycobacterium tuberculosis and use this system as a drug-testing platform for the screening of small-molecule therapeutics against multi-drug resistant M. tuberculosis.</p>


Shaorong Chong of New England Biolabs in the U.S. will synthetically reconstruct essential biological processes of Mycobacterium tuberculosis and use this system as a drug-testing platform for the screening of small-molecule therapeutics against multi-drug resistant M. tuberculosis.